Armistice Capital’s Solid Biosciences SLDB Stock Holding History

Armistice Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.7M	Buy	4,278,000 +1,078,000	+34%	+$8.17M	0.52%	30
2026 Q1	$23M	Buy	3,200,000 +588,000	+23%	+$3.78M	0.41%	50
2025 Q4	$14.7M	Buy	2,612,000 +1,676,000	+179%	+$9.08M	0.18%	87
2025 Q3	$5.78M	Buy	936,000 +536,000	+134%	+$3.13M	0.09%	108
2025 Q2	$1.95M	Buy	+400,000	New	+$1.41M	0.03%	134
2019 Q1	–	Sell	-22,133	Closed	-$8.9M	–	84
2018 Q4	$8.9M	Buy	22,133 +11,200	+102%	+$5.27M	0.67%	33
2018 Q3	$7.74M	Sell	10,933 -1,067	-9%	-$670K	0.46%	50
2018 Q2	$6.41M	Buy	+12,000	New	+$3.69M	0.42%	57

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Armistice Capital's SLDB Position: Q2 2026 in Review

Armistice Capital increased its Solid Biosciences (SLDB) stake by 34% in Q2 2026, buying an estimated $8.17M and bringing the position to 4,278,000 shares worth $42.7M. The position accounts for 0.52% of the portfolio, ranked #30.

Armistice Capital first reported a position in SLDB in Q2 2018 and has held it in 8 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Armistice Capital held 4,278,000 shares of Solid Biosciences worth $42.7M as of Q2 2026.
Armistice Capital bought 1,078,000 Solid Biosciences shares in Q2 2026, an estimated $8.17M.
Solid Biosciences made up 0.52% of Armistice Capital's portfolio in Q2 2026, its #30 holding.
Armistice Capital first reported a position in Solid Biosciences in Q2 2018 and has held it in 8 quarters since.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.